首页> 外文期刊>The Internet Journal of Neuromonitoring >Deep Brain Stimulation for Treatment of Parkinson’s Disease Deep brain stimulation, Parkinson’s disease, subthalamic nucleus, stereotactic surgery
【24h】

Deep Brain Stimulation for Treatment of Parkinson’s Disease Deep brain stimulation, Parkinson’s disease, subthalamic nucleus, stereotactic surgery

机译:深层脑刺激治疗帕金森氏病深层脑刺激,帕金森氏病,丘脑下核,立体定向手术

获取原文
       

摘要

With the evolution of deep brain stimulation (DBS), stereotactic operative treatment of drug resistant Parkinson’s Disease experiences a renaissance. Refined operative techniques using computerized image-fusion programs, intraoperative microrecording and macrostimulation have made the targeting of the region of interest easier. Deep brain stimulation of the subthalamic nucleus is able to reduce major symptoms as tremor, rigor and bradykinesia. Short and middle-term as well as long-term studies have confirmed these results.The rate of intra- and perioperative complications is around 1-2%. However, during the follow-up period hardware-related complications can increase to 4-20%. This is an overview about history, indications, operative technique and results of deep brain stimulation based on the actual literature. Introduction During last years surgical procedures have played an important role in the treatment of drug-refractory central movement disorders. Spiegel und Wycis (24) introduced the stereotactic techniques in neurosurgery: it allows to hit every brain area three-dimensionally in a range of millimeters. In the beginning the application of this procedure was used to treat patients with severe pain syndromes (22). This was followed by interventions in patients with movement disorders and psychiatric diseases. Lacking alternative treatment the so-called “stereotactic lesional procedures” by damage of intracerebral nuclei were the method of choice in the late sixties (13,15). However, with the introduction of Levodopa, there was a loss of interest in stereotactic neurosurgery. Over a long time patients with tremor which was drug resistant remain the only indication for “thalamotomy”, whereas in bilateral tremor one side was left untreated.In 1986 Benabid performed for the first time a combination of unilateral thalamotomy and contralateral thalamic stimulation in a patient with bilateral tremor (2). The results were such successful, that Deep Brain Stimulation (DBS) of the Ventral intermediate nucleus (Vim) of the thalamus has been applied as first choice operative treatment for tremor in the following years (1). The EC-certification for this indication was obtained in 1995.Using the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) monkey model, Benazzouz et al. (4) found in 1993 that high frequency stimulation of the nucleus suthalamicus (STN) has a remarkable positive effect on rigor and bradykinesia. This resulted in a change of paradigm for operative treatment of PD. The STN was defined as the new target for DBS (3/18), since it influences positively not only Tremor, but also akinesia and rigor. The EC-certification of DBS for the operative treatment of tremor, rigor and akinesia was obtained in 1998. The great advantage of this procedure versus lesional procedures is the simultaneous stimulation of both hemispheres and/or different target points. Moreover side effects are reversible by regulation of stimulation parameters (7/11) and future treatment options e.g. neurotransplantation are not excluded.The exact mechanism underlying the beneficial effect of DBS is still unclear and remains a field of active research. It seems to be a combination of inhibition of neurons, modulation of abnormal patterns of activity, and activation of axons (19). Indications and Contraindications Besides Parkinson Disease (PD), dystonia and tremor of different origin are the standard indications for DBS. Stereotactic treatment of other neurologic-psychiatric diseases as cluster-headache, epilepsy or obsessive-compulsive disorders (OCD) is actually experimental.The table 1 gives shows the indications for DBS in PD patients. Table 1: Indications for DBS in Parkinson’s DiseaseContraindications are dementia or psychotic disorders, multiple system atrophia (MSA) and other neurological diseases such as brain tumors or brain atrophy. Furthermore internistic pathologies e.g. coagulation disorders preclude the operative procedure.Operative Techn
机译:随着深部脑刺激(DBS)的发展,对耐药性帕金森氏病的立体定向手术治疗经历了复兴。使用计算机图像融合程序,术中微记录和宏观刺激的精细手术技术使目标区域的瞄准变得更加容易。丘脑底核的深部大脑刺激能够减轻震颤,僵直和运动迟缓等主要症状。短期和中期以及长期研究都证实了这些结果。术中和围手术期并发症的发生率约为1-2%。但是,在随访期间,与硬件相关的并发症可能会增加到4-20%。这是根据实际文献对深部脑刺激的历史,适应症,手术技术和结果进行的概述。简介近年来,外科手术在药物难治性中枢运动障碍的治疗中发挥了重要作用。 Spiegel und Wycis(24)介绍了神经外科中的立体定向技术:它可以在毫米范围内三维地撞击每个大脑区域。最初,该程序的应用被用于治疗患有严重疼痛综合征的患者(22)。其次是对运动障碍和精神病患者的干预。缺乏替代治疗方法是六十年代后期选择的方法,即通过破坏脑内核来进行所谓的“立体定向病变手术”(13,15)。然而,随着左旋多巴的引入,对立体定向神经外科手术的兴趣下降。长期以来,耐药的震颤患者仍然是“丘脑功能不全”的唯一指征,而在双侧震颤中,一侧没有得到治疗。1986年,贝纳比德首次对患者进行单侧丘脑功能和对侧丘脑刺激相结合双侧震颤(2)。结果是如此成功,以至于丘脑腹侧中间核(Vim)的深部脑刺激(DBS)在接下来的几年中被用作震颤的首选手术治疗方法(1)。 Benazzouz等人于1995年获得了该适应症的EC认证。使用1-甲基-4-苯基-1,2,3,6-四氢吡啶(MPTP)猴子模型。 (4)在1993年发现,高频刺激suthalamicus核(STN)对严格和运动迟缓具有明显的积极作用。这导致PD手术治疗范例的改变。 STN被定义为DBS的新目标(3/18),因为它不仅对震颤产生积极影响,而且还对运动障碍和僵化产生积极影响。 1998年获得了DBS的EC认证,用于手术治疗震颤,僵直和运动障碍。与病变手术相比,该手术的最大优势是可以同时刺激半球和/或不同的目标点。而且,通过调节刺激参数(7/11)和将来的治疗选择,例如副作用,副作用是可逆的。不能排除神经移植。DBS有益作用的确切机制尚不清楚,仍是积极研究的领域。它似乎是抑制神经元,调节异常活动模式和激活轴突的组合(19)。适应症和禁忌症除了帕金森氏病(PD)外,不同起源的肌张力障碍和震颤是DBS的标准适应症。其他神经精神疾病如立体头痛,癫痫或强迫症(OCD)的立体定向治疗实际上是实验性的。表1给出了PD患者DBS的适应症。表1:帕金森氏病中DBS的适应症禁忌症包括痴呆症或精神病,多系统萎缩症(MSA)以及其他神经系统疾病,例如脑瘤或脑萎缩。此外,内部病理学例如凝血功能障碍排除了手术过程。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号